9 November 2016



ASX Announcement

Mach7 Poised for Growth -Awarded UK NHS Approved Supplier Status

- Mach7 rapidly extends reach into UK market as approved supplier of enterprise image management systems
- Strong growth in UK healthcare spending yields significant market opportunity

Melbourne, Australia; 9 November 2016: Mach7 Technologies Limited (**Mach7** or the **Company**) (ASX:**M7T**), a leader in the global enterprise imaging market, today announced it has been approved by the National Health Service (**NHS**) of the United Kingdom to supply the full suite of Mach7 software solutions across the UK NHS.

The NHS Supply Chain Framework lists organisations that have been assessed to deliver products and services to the NHS based on quality and commercial criteria.

Following a rigorous formal tender process whereby the NHS Supply Chain evaluated participating vendors on financial criteria, clinical acceptability and ease of use, Mach7 was awarded the NHS Framework Agreement due to the value and quality of its solution.

Inclusion on the Framework is required for all vendor solutions procured by NHS hospitals, and with upwards of 80% of all hospitals and health services in the UK managed via the NHS, the Framework Agreement provides Mach7 unprecedented access to the UK healthcare market.

Further, this route to the UK market should result in reduced procurement times and costs for Mach7 in securing additional software licences for its award-winning software solutions. Mach7 is currently participating in multiple tenders throughout the UK and the awarding of the Framework Agreement should enhance Mach7's positioning among these competitive bids.

Albert Liong, CEO Mach7 Technologies, said, "The UK healthcare market is experiencing significant growth and is well-positioned to adopt the advanced enterprise imaging technology that Mach7 offers. We look forward to expanding our reach with the NHS and advancing patient care throughout the UK."

- ENDS



ASX Announcement

9 November 2016

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced <u>clinical viewing</u> and optimised <u>vendor neutral archiving</u> solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit <u>www.mach7t.com</u>

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit <u>www.3dmedical.com.au</u>

Contacts:

Albert Liong CEO +1 650 743 0167 (U.S.) albert.liong@mach7t.com Jenni Pilcher CEO Australia, CFO +61 3 9646 2222 (Australia) jenni.pilcher@mach7t.com Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com